Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 15

PMID 33718183

Citations 10

Authors

Yulong Fu

Anqi Wang

Jieqi Zhou

Wei Feng

Minhua Shi

Xiao Xu

Hongqing Zhao

Liming Cai

Jian Feng

Xuedong Lv

Xiaodong Zhang

Wenjing Xu

Zhengrong Zhang

Guoer Ma

Jian Wang

Tong Zhou

Dahai Zhao

Haohui Fang

Zeyi Liu

Jian-An Huang

Affiliations

Soon will be listed here.

Abstract

Background: Non-small cell lung cancer (NSCLC) patients treated with first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) almost always acquire resistance, and the development of novel techniques analyzing circulating tumor DNA (ctDNA) have made it possible for liquid biopsy to detect genetic alterations from limited amount of DNA with less invasiveness. While a large amount of patients with EGFR exon 21 p.Thr790 Met (T790M) benefited from osimertinib treatment, acquired resistance to osimertinb has subsequently become a growing challenge.

Methods: We performed tissue and liquid rebiopsy on 50 patients with EGFR-mutant NSCLC who acquired resistance to first-generation EGFR-TKIs. Plasma samples underwent droplet digital PCR (ddPCR) and next-generation sequencing (NGS) examinations. Corresponding tissue samples underwent NGS and Cobas EGFR Mutation Test v2 (Cobas) examinations.

Results: Of the 50 patients evaluated, the mutation detection rates of liquid biopsy group and tissue biopsy group demonstrated no significant differences (41/48, 85.4% vs. 44/48, 91.7%; OR=0.53, 95% CI=0.15 to 1.95). Overall concordance, defined as the proportion of patients for whom at least one identical genomic alteration was identified in both tissue and plasma, was 78.3% (36/46, 95% CI=0.39 to 2.69). Moreover, our results showed that almost half of the patients (46%, 23/50) resistant to first-generation EGFR-TKI harbored p.Thr790 Met (T790M) mutation. 82.6% (19/23) of the T790M positive patients were analyzed by liquid biopsy and 60.9% (14/23) by tumor tissue sequencing. Meanwhile, a wide range of uncommon mutations was detected, and novel mechanisms of osimertinib resistance were discovered. In addition, 16.7% (2/12) of the T790M positive patients with either TP53 R237C or KRAS G12V failed to benefit from the subsequent osimertinib treatment.

Conclusion: Our results emphasized that liquid biopsy is applicable to analyze the drug resistance mechanisms of NSCLC patients treated with EGFR-TKIs. Moreover, we discovered two uncommon mutations, TP53 R273C and KRAS G12V, which attenuates the effectiveness of osimertinib.

Citing Articles

Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non-Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study.

Dawoud R, Saman H, Rasul K, Jibril F, Sahal A, Al-Okka R Clin Med Insights Oncol. 2024; 18:11795549241272490.

PMID: 39416762 PMC: 11481063. DOI: 10.1177/11795549241272490.

CRISPR-mediated ablation of TP53 and EGFR mutations enhances gefitinib sensitivity and anti-tumor efficacy in lung cancer.

Yoon A, Lee S, Kim J, Park Y, Koo T, Yun C Mol Ther. 2024; 32(10):3618-3628.

PMID: 39066480 PMC: 11489544. DOI: 10.1016/j.ymthe.2024.07.017.

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer.

Hu S, Ming H, He Q, Ding M, Ding H, Li C Front Oncol. 2024; 14:1314301.

PMID: 38651148 PMC: 11033419. DOI: 10.3389/fonc.2024.1314301.

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?.

Li Y, Kong S, Liu Y, Yang Y, Zhang H J Clin Med. 2023; 12(4).

PMID: 36835972 PMC: 9966257. DOI: 10.3390/jcm12041438.

KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration.

Yang Y, Zhang H, Huang S, Chu Q J Clin Med. 2023; 12(2).

PMID: 36675641 PMC: 9861148. DOI: 10.3390/jcm12020709.

References

Jovelet C, Ileana E, Le Deley M, Motte N, Rosellini S, Romero A . Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. Clin Cancer Res. 2016; 22(12):2960-8. DOI: 10.1158/1078-0432.CCR-15-2470. View

Overman M, Modak J, Kopetz S, Murthy R, Yao J, Hicks M . Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. J Clin Oncol. 2012; 31(1):17-22. PMC: 5545102. DOI: 10.1200/JCO.2012.43.1718. View

Ohashi K, Sequist L, Arcila M, Moran T, Chmielecki J, Lin Y . Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012; 109(31):E2127-33. PMC: 3411967. DOI: 10.1073/pnas.1203530109. View

Goss G, Tsai C, Shepherd F, Bazhenova L, Lee J, Chang G . Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016; 17(12):1643-1652. DOI: 10.1016/S1470-2045(16)30508-3. View

Nishiyama A, Takeuchi S, Adachi Y, Otani S, Tanimoto A, Sasaki M . MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. Cancer Sci. 2020; 111(10):3813-3823. PMC: 7540985. DOI: 10.1111/cas.14593. View

Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y . Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0). Cancer Sci. 2018; 109(9):2980-2985. PMC: 6125473. DOI: 10.1111/cas.13730. View

Mok T, Wu Y, Ahn M, Garassino M, Kim H, Ramalingam S . Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2016; 376(7):629-640. PMC: 6762027. DOI: 10.1056/NEJMoa1612674. View

Labbe C, Cabanero M, Korpanty G, Tomasini P, Doherty M, Mascaux C . Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer. 2017; 111:23-29. DOI: 10.1016/j.lungcan.2017.06.014. View

Ihle N, Byers L, Kim E, Saintigny P, Lee J, Blumenschein G . Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012; 104(3):228-39. PMC: 3274509. DOI: 10.1093/jnci/djr523. View

10.

Stinchcombe T, Johnson G . MEK inhibition in non-small cell lung cancer. Lung Cancer. 2014; 86(2):121-5. PMC: 4406476. DOI: 10.1016/j.lungcan.2014.09.005. View

11.

Aung K, Board R, Ellison G, Donald E, Ward T, Clack G . Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J. 2011; 4(1-4):11-21. PMC: 3051045. DOI: 10.1007/s11568-011-9149-2. View

12.

Pao W, Miller V, Politi K, Riely G, Somwar R, Zakowski M . Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2(3):e73. PMC: 549606. DOI: 10.1371/journal.pmed.0020073. View

13.

Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y . Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010; 16(22):5489-98. DOI: 10.1158/1078-0432.CCR-10-1371. View

14.

VanderLaan P, Rangachari D, Mockus S, Spotlow V, Reddi H, Malcolm J . Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017; 106:17-21. PMC: 5351777. DOI: 10.1016/j.lungcan.2017.01.011. View

15.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

16.

Planchard D, Loriot Y, Andre F, Gobert A, Auger N, Lacroix L . EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015; 26(10):2073-8. DOI: 10.1093/annonc/mdv319. View

17.

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

18.

Yang J, Ahn M, Kim D, Ramalingam S, Sequist L, Su W . Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017; 35(12):1288-1296. DOI: 10.1200/JCO.2016.70.3223. View

19.

Li J, Yang L, Gaur S, Zhang K, Wu X, Yuan Y . Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy. Hum Mutat. 2014; 35(5):575-84. DOI: 10.1002/humu.22528. View

20.

Sorber L, Zwaenepoel K, Deschoolmeester V, Van Schil P, Van Meerbeeck J, Lardon F . Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer. 2016; 107:100-107. DOI: 10.1016/j.lungcan.2016.04.026. View